Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...

Recursion Pharmaceuticals expanded its collaboration with Citeline to integrate real world data into its AI enabled ClinTech Platform. The partnership is aimed at refining clinical trial design and ...

Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

I'm building a simple FastMCP Server. The application is being compiled with Nuitka. I'm observing a weird behavior where the Server runs into Segmentation Faults when DEBUG Mode is enabled. On ...

Recursion Pharmaceuticals RXRX is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability ...

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...